Regioselective Synthesis of 1,3,5-Trisubstituted Pyrazoles
作者:Vidya G. Desai、Pooja C. Satardekar、Sampada Polo、Kashinath Dhumaskar
DOI:10.1080/00397911.2010.531492
日期:2012.3.15
Abstract A new and a simple approach toward synthesis of 1,3,5-trisubstitutedpyrazoles from chalcone arylhydrazones via oxidative cyclization has been achieved. 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone was successfully used as an oxidizing agent to give excellent yields of pyrazoles. GRAPHICAL ABSTRACT
Convenient Synthesis of Highly Functionalized Pyrazolines via Mild, Photoactivated 1,3-Dipolar Cycloaddition
作者:Yizhong Wang、Claudia I. Rivera Vera、Qing Lin
DOI:10.1021/ol7017328
日期:2007.10.1
cycloaddition procedure was successfully developed for the synthesis of polysubstituted pyrazolines. This procedure involved the in situ generation of the reactive nitrile imine dipoles using a hand-held UV lamp at 302 nm, followed by spontaneous cycloaddition with a broad range of 1,3-dipolarophiles with excellent solvent compatibility, functional group tolerance, regioselectivity, and yield.
Intramolecular oxidative C–N bond formation under metal-free conditions: One-pot global functionalization of pyrazole ring
作者:Mohit K. Tiwari、Ashif Iqubal、Parthasarathi Das
DOI:10.1016/j.tet.2022.133059
日期:2022.11
of intermediate free-radical species followed by intramolecular oxidative C–N bondformation afforded the desired pyrazole moiety. The synthetic versatility of this methodology is further highlighted by preparing a diverse range of substrates including di-/tri-/and tetra-substituted pyrazoles, and applying the methodology in the practical synthesis of bioactive scaffolds.
Compositions of a cyclooxygenase-2 selective inhibitor and phosphodiesterase inhibitor for the treatment of ischemic mediated central nervous system disorders or injury
申请人:Stephenson T. Diane
公开号:US20050130971A1
公开(公告)日:2005-06-16
The present invention provides compositions and methods for the treatment of central nervous system disorders. In some aspects, the invention provides a combination therapy for the treatment of a central nervous system ischemic mediated disorder comprising the administration to a subject of a PDE inhibitor in combination with a cyclooxygenase-2 selective inhibitor.